
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is a global leader in bronchoscopic lung volume reduction technology, providing a minimally invasive solution for patients with severe emphysema. The recent leadership transition and emphasis on commercial focus and operating discipline indicate a commitment to improving execution and driving revenue growth. The company's strong financials and adequate runway suggest a positive outlook, but consistent execution and increased procedure growth will be key factors for investors to regain confidence in the company's potential.
Bears say
Pulmonx is facing challenges in the U.S. and China, with disruption in U.S. sales and the absence of China sales due to registration renewal. Despite this, management remains optimistic and expects a sequential improvement in revenue growth through 2026 and a return to growth in both U.S. and international markets in the back half of the year. However, the company's cash burn of $23M and the decline in U.S. sales in the latest quarter raise concerns about their financial stability.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares